#44/2
7/9/99
C. Style

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

COATES et al. Examiner: J. Ford

Serial No.: 07/835,964 Group Art Unit: 1611

Filed: February 20, 1992 :

For: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

REQUEST AND FIRST SUBMISSION FOR TRANSITIONAL PRACTICE UNDER 37 C.F.R. §1.129(a)

Assistant Commissioner for Patents
Washington, DC 20231

SIR:

As a first submission pursuant to 37 C.F.R. §1.129, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 23, 30, 35, 36, and 40-42.

Please amend claims 25, 26, 28, 29, 31, and 37 as follows:

25. (Amended Twice) A method for treating a human [mammal] suffering from HIV infection comprising administering to said mammal a pharmaceutical composition comprising: the compound (-)-cis-4-amino-1-(2-hydroxmethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, and a pharmaceutically acceptable carrier,

wherein said pharmaceutical composition further comprises another [antiviral] agent having antiviral activity, and

wherein the amount of the (+)-enantiomer corresponding to said compound is present in said composition is no more than 5% w/w, relative to the combined weight of (-) and (+)-enantiomers.

26. (Amended Twice) A method according to claim 25, wherein said [antiviral] agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport

IAFG-14

35